| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Isotope-Labeled Compounds (non-radioactive tracer), P2Y12 Receptor (indirectly, as a tracer for clopidogrel).
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
No biological activity data are reported for the labeled form. As an internal standard, it does not exhibit direct in vitro activity. The non-labeled clopidogrel inhibits ADP-induced platelet aggregation in human platelet-rich plasma with IC50 values in the low micromolar range. |
| ln Vivo |
In vivo, clopidogrel is orally active and potently inhibits ex vivo platelet aggregation in animal models and humans. In rat thrombosis models, it reduces thrombus formation dose-dependently.
|
| Enzyme Assay |
For cell-free assays, a typical protocol: prepare plasma samples containing clopidogrel, add (Rac)-Clopidogrel-d3 internal standard, extract via liquid-liquid extraction or protein precipitation, centrifuge, evaporate, reconstitute in mobile phase, and analyze by LC-MS/MS.
|
| Cell Assay |
No specific cell-based assays are performed. The parent drug is tested in platelet aggregation assays using human or animal platelet-rich plasma stimulated with ADP in a light aggregometer.
|
| Animal Protocol |
No animal studies are conducted directly with the labeled internal standard. For unlabeled clopidogrel, typical in vivo PK studies involve oral administration to rats or dogs, followed by serial blood collection, sample processing with deuterated internal standard, and LC-MS/MS analysis of active metabolite concentrations.
|
| ADME/Pharmacokinetics |
PK properties of clopidogrel: oral bioavailability ~50%, extensively metabolized by CYP450 enzymes (CYP2C19, CYP3A4) to active metabolite, peak plasma concentration achieved in 1 hour, half-life approximately 6 hours. The labeled standard is not subjected to PK analysis.
|
| Toxicity/Toxicokinetics |
Unlabeled clopidogrel has a well-established safety profile with adverse effects including bleeding, gastrointestinal disturbances, rash, and diarrhea. Rare but serious side effects include thrombotic thrombocytopenic purpura (TTP). The deuterated standard is for research use only.
|
| References | |
| Additional Infomation |
Clopidogrel is FDA-approved for reducing cardiovascular events in patients with acute coronary syndrome, myocardial infarction, stroke, or established peripheral artery disease. The racemic labeled standard is used for analytical method development but is not approved as a drug. It is for research only.
|
| Exact Mass |
422.045
|
|---|---|
| CAS # |
2468372-74-7
|
| Related CAS # |
(±)-Clopidogrel bisulfate;135046-48-9
|
| PubChem CID |
53394723
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
26
|
| Complexity |
463
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])OC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3.OS(=O)(=O)O
|
| InChi Key |
FDEODCTUSIWGLK-NIIDSAIPSA-N
|
| InChi Code |
InChI=1S/C16H16ClNO2S.H2O4S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14;1-5(2,3)4/h2-5,7,9,15H,6,8,10H2,1H3;(H2,1,2,3,4)/i1D3;
|
| Chemical Name |
sulfuric acid;trideuteriomethyl 2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
